Clinical Trials
3 trialsNCT05907304 2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1 Active not recruiting
NCT02974725 2025-04-13
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Novartis
Phase 1 Terminated
NCT02607813 2022-12-21
Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
Novartis
Phase 1 Terminated